NeoGenomics had its Relative Strength (RS) Rating upgraded from 80 to 83 Monday.
This exclusive rating from Investor's Business Daily identifies market leadership with a 1 (worst) to 99 (best) score. The grade shows how a stock's price behavior over the trailing 52 weeks stacks up against all the other stocks in our database.
Over 100 years of market history reveals that the stocks that go on to make the biggest gains typically have an 80 or better RS Rating as they launch their biggest runs.
Looking For The Best Stocks To Buy And Watch? Start Here
Now is not an ideal time to jump in since it isn't near a proper buy zone, but see if the stock is able to establish and enter a buying range in heavy volume.
NeoGenomics posted 0% EPS growth in the latest quarterly report, while sales growth came in at 10%.
The company earns the No. 5 rank among its peers in the Medical-Services industry group. Hims & Hers Health is the No. 1-ranked stock within the group.
RELATED:
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
